The emergence of immune checkpoint inhibitors (ICIs), specifically antibodies targeting the PD-1/PD-L1 axis, has reshaped the treatment landscape for various cancers including non-small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and cancer.